Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

DeveloGen licenses DiaPep277 to start-up Andromeda Biotech; later concludes

Executive Summary

The Israeli subsidiary of DeveloGen AG (metabolic and endocrine disorders) has licensed its DiaPep277 candidate to newly formed diabetic therapeutics developer Andromeda Biotech. DiaPep277 is a peptide derived from human heat-shock protein HSP60, an immunomodulator known for preventing the destruction of insulin-secreting pancreatic cells in Type I diabetes.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies